TEK and glaucoma: Indeed, a recent study has demonstrated the effectiveness of targeting the Angpt-TEK signaling pathway in a mouse model of glaucoma using an antibody which increases the signaling ability of the context-dependent, weak TEK agonist ANGPT2 by clustering it into higher-order multimers (Kim et al., 2017; Park et al., 2016).